Verona Pharma plc - American Depositary Shares (VRNA)
104.78
+0.04 (0.04%)
NASDAQ · Last Trade: Jul 17th, 11:25 AM EDT
Detailed Quote
Previous Close
104.74
Open
104.79
Bid
104.77
Ask
104.78
Day's Range
104.75 - 104.81
52 Week Range
18.51 - 104.99
Volume
2,350,231
Market Cap
50.32B
PE Ratio (TTM)
-419.12
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
6,699,286
Chart
About Verona Pharma plc - American Depositary Shares (VRNA)
Verona Pharma is a biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company concentrates on the discovery and development of impactful drugs that address significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Their research and pipeline involve novel mechanisms of action, aiming to improve patient outcomes and quality of life through enhanced treatment options. Verona Pharma utilizes its expertise in drug development to advance potential therapies from preclinical stages through clinical trials. Read More
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depository Share that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders.
BALA CYNWYD, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.
